JP2022521173A - 癌治療 - Google Patents

癌治療 Download PDF

Info

Publication number
JP2022521173A
JP2022521173A JP2021547154A JP2021547154A JP2022521173A JP 2022521173 A JP2022521173 A JP 2022521173A JP 2021547154 A JP2021547154 A JP 2021547154A JP 2021547154 A JP2021547154 A JP 2021547154A JP 2022521173 A JP2022521173 A JP 2022521173A
Authority
JP
Japan
Prior art keywords
eldaphytinib
specifically
cancer
daily
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021547154A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020165181A5 (https=
JP2022521173A5 (https=
Inventor
エリザベス オハガン，アン
ポール，ピーター マリー ゼット． デ
ナラヤン アヴァダニ，アンジャリ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022521173A publication Critical patent/JP2022521173A/ja
Publication of JPWO2020165181A5 publication Critical patent/JPWO2020165181A5/ja
Publication of JP2022521173A5 publication Critical patent/JP2022521173A5/ja
Priority to JP2025162216A priority Critical patent/JP2026016402A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021547154A 2019-02-12 2020-02-11 癌治療 Withdrawn JP2022521173A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025162216A JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19156806.2 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025162216A Division JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Publications (3)

Publication Number Publication Date
JP2022521173A true JP2022521173A (ja) 2022-04-06
JPWO2020165181A5 JPWO2020165181A5 (https=) 2023-02-21
JP2022521173A5 JP2022521173A5 (https=) 2023-02-21

Family

ID=69467563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547154A Withdrawn JP2022521173A (ja) 2019-02-12 2020-02-11 癌治療
JP2025162216A Pending JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025162216A Pending JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Country Status (16)

Country Link
US (1) US20220168298A1 (https=)
EP (1) EP3923942A1 (https=)
JP (2) JP2022521173A (https=)
KR (1) KR20210126654A (https=)
CN (1) CN113423402A (https=)
AU (1) AU2020223467B2 (https=)
BR (1) BR112021015686A2 (https=)
CA (1) CA3126959A1 (https=)
IL (1) IL285466A (https=)
JO (1) JOP20210216A1 (https=)
MA (1) MA54932A (https=)
MX (1) MX2021009670A (https=)
PH (1) PH12021551949A1 (https=)
SG (1) SG11202107850VA (https=)
TW (1) TWI863962B (https=)
WO (1) WO2020165181A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4063516A1 (en) * 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
AU2016341445B2 (en) * 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 11, JPN7024000154, 2010, pages 1850 - 1855, ISSN: 0005701164 *

Also Published As

Publication number Publication date
EP3923942A1 (en) 2021-12-22
PH12021551949A1 (en) 2022-07-18
AU2020223467B2 (en) 2025-12-04
KR20210126654A (ko) 2021-10-20
CA3126959A1 (en) 2020-08-20
SG11202107850VA (en) 2021-08-30
MX2021009670A (es) 2021-09-08
JOP20210216A1 (ar) 2023-01-30
CN113423402A (zh) 2021-09-21
AU2020223467A1 (en) 2021-08-05
TW202045173A (zh) 2020-12-16
JP2026016402A (ja) 2026-02-03
MA54932A (fr) 2021-12-22
TWI863962B (zh) 2024-12-01
IL285466A (en) 2021-09-30
WO2020165181A1 (en) 2020-08-20
BR112021015686A2 (pt) 2021-10-26
US20220168298A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
TW202027746A (zh) 用於治療三陰性乳癌之組合療法
JP2026016402A (ja) 癌治療
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2022527702A (ja) 小細胞肺がんの治療におけるキアウラニブの使用
EA052711B1 (ru) Лечение рака
HK40103983A (en) Cancer treatment
HK40013982A (en) Cancer treatment
EA051616B1 (ru) Лечение рака
WO2023209611A1 (en) Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
CN116887833A (zh) 某些化学实体、组合物和方法
HK40018978A (en) Cancer treatment
HK40018978B (en) Cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251015